Cargando…
Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
BACKGROUND: A subcutaneous (SC) formulation of rituximab (MabThera(®)/Rituxan(®)) has been developed that could reduce administration time and improve patient satisfaction with treatment. The Rituximab Administration Satisfaction Questionnaire (RASQ) was created to assess patients’ perceptions and s...
Autores principales: | Theodore-Oklota, Christina, Humphrey, Louise, Wiesner, Christof, Schnetzler, Gabriel, Hudgens, Stacie, Campbell, Alicyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028167/ https://www.ncbi.nlm.nih.gov/pubmed/27695295 http://dx.doi.org/10.2147/PPA.S108489 |
Ejemplares similares
-
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019) -
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016) -
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
por: Ponzetti, Clemente, et al.
Publicado: (2016) -
Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016) -
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)